Soligenix (SNGX) Climbs on Promising Bundibugyo Virus Vaccine Data From Thermostable Platform

Soligenix Inc. (NASDAQ: SNGX) shares rose on May 27, 2026, after the company reported that its thermostable vaccine platform showed robust preclinical results against Bundibugyo virus, a filovirus causing severe hemorrhagic fever. The announcement drove investor optimism over the platform’s capacity to enable vaccines that bypass cold-chain requirements. The candidate generated strong immune responses without refrigeration, the company said, enhancing its viability for deployment in resource-limited areas. Soligenix is leveraging the same platform for vaccines targeting Marburg virus and Sudan ebolavirus. No specific percentage gain was immediately available, but the stock moved higher in midday trading.